Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Respectfully, that is what was said prior to the previous reverse split. At the end of the day King may be a good lab rat but in any other company he and this board would have fired. To add insult to injury they continue with their bonus and high salaries. For the record, I have a lot of shares and have been in since the 2000 ish time frame. They either need to produce, make a deal or resign!
July 28, 2015 — 3:26 PM EDT
Share on FacebookShare on Twitter
Don't Miss Out — Follow Bloomberg On
Facebook Twitter Instagram YouTube
Share on Facebook
Share on Twitter
Pfizer Inc. Chief Executive Officer Ian Read said he’s on the hunt for an acquisition to build up the company’s collection of innovative drugs, five months after agreeing to a $17 billion deal to bolster the unit that sells older products.
Pfizer’s been reviewing whether to split into two parts, with one housing potentially lucrative new drugs and another encompassing the slower-growing, established products. Its deal in February to buy injectable drugmaker Hospira Inc. supported the latter and also gave Pfizer access to a growing market for biologic imitations of competitors’ drugs.
Now Pfizer’s management team is looking for products or a business to help make up for patent expirations of what once were blockbuster drugs. And a deal could be big or small.
“I don’t think we’re looking at limitations on size,” Read said in an interview. “With size sometimes comes complexity.”
While Read didn’t name specific targets, investors routinely parse his public comments for clues about which companies he’s looking at. GlaxoSmithKline Plc and Shire Plc, both based in the U.K., have been bandied about ever since Pfizer ended its six-month, $120 billion pursuit of London-based AstraZeneca Plc after failing to reach an agreement on price. Relocating to a U.K. address could help Pfizer save on taxes.
After Allergan Plc agreed Monday to sell its generic-drug business to Teva Pharmaceutical Industries Ltd., its portfolio of brand-name medications became subject to speculation, including as a target for Pfizer. But the Teva deal is giving Allergan enough cash that it could pursue its own acquisition of as much as $100 billion, according to Bloomberg Intelligence.
Track Record
Pfizer has a proven track record of integrating large companies, said Chief Financial Officer Frank D’Amelio. In 2000, New York-based Pfizer paid $116 billion for Warner-Lambert Co.; in 2003 it spent $60 billion for Pharmacia Corp.; and in 2009 it paid more than $60 billion for Wyeth LLC -- acquisitions that gave Pfizer blockbuster products like Lipitor and Prevnar.
“It’s something that I consider a core competency of the company -- we’re good at it,” D’Amelio said in an interview. “One of the nice things about Pfizer is we have the capacity to do any size deal that we want.”
Could this possibly mean the look-ins are controlled by specific dates as opposed to population? This seems highly unlikely, however! Or, can it mean the number of patients at a specific number of days post treatment. Again, questionable!
I do believe simulations, while valiant in their attempt, can not be relied upon since we do not know how the company's internal protocol defines or quantifies "On Track."
Posted two hours ago on Sierra!
Covert Acquisition Discussions Ending With Buyout Announcement Coming From Peregrine Pharmaceuticals (PPHM) Ventures Sierra Equity
Latest Projections: Covert Acquisition Discussions Ending With Buyout Announcement Coming From Peregrine Pharmaceuticals (PPHM) Ventures Sierra Equity. Shares of PPHM finished higher up over 4% at the end of Friday's session. More to follow.....check back as Sierra pursues her leads, look for the official news, when it breaks remember Sierra called this first!
I called his chambers today and spoke with one of his clerks. I also spoke with RG2 claims and they confirmed my check was mailed yesterday.
I also called Kisha and left a message. Do you have any idea what the restitution pool of money from DOJ is?
Judge Hittner heard arguments on Dial case regarding final issues (I believe on restitution)and a decision is expected in about 90 days.
RG2 just advised me that they mailed my check yesterday. They are paying approximately 26.66% of recognized loss. My question is: Is there a second pool of money in DOJ?
the question is, who owns MCET stock besides LaJolla's +/- 10%
United States Attorneys Office
Southern District of Texas
1000 Louisiana
Suite 2300
Houston, Texas 77002
Attention: Victim/Witness Coordinator
Olga De La Rosa
I believe she is the new victim/witness coordinator replacing Keisha, at least on this case. She told me the case has been sitting on the Judge's desk since April. She was pleasant enough. I have the sense that unless we take action and start writing letters, there will be little motivation, incentive or desire to act on this case. It really can be simply a matter of a heavy workload in the office and this not being a high profile or priority matter.
B2B I spoke with Olga from Us Attorney's Office. She is recommending letters be sent to her asking for the status of restitution. She indicates she can then hand deliver them to the Restitution Unit and ask for an explanation as to what is going on. She states she can simply call them, but when it is documented it is more effective
Do you have her telephone number?
C/P I agree, perhaps it was the original messenger's personal opinion or interpretation. Under the circumstances, I think PPHM is being extremely circumspect. I suspect there are more eyes on these trials than certain outside entities would like there to be.
Folks:
I seem to recall a conversation here, and attributed to perhaps I/R, that BY DESIGN information concerning the trial locations were not completely accurate. If I recall correctly, zip codes were specifically mentioned. I had the sense at the time that this was done for security purposes. Obviously, I cannot validate the information, but it is my vague recollection, so don't shoot the messenger as I have been long here since 03/2000.
Hi B2B I am a little confused here. Are we (someday in the future) going to receive two restitution streams. One from SEC and one from DOJ?
And the winner will be the one that takes out PPHM (Peregrine Pharma.)
anybody, where is the broadcast for today?
looks to be less than 20% for me
I just received my letter as to how much I am getting back. Not too happy with the amount, but more than I have now from this stock.
GSK reports yet another Phase III drug failure......
I guess you are not able to quantify it.
And how many shares do you suggest Roche owns?
I still wonder if an entity is taking this private!
Prayers for you and your family.
What ever happened to that security (MXMI) I had 6666 now have 16 of restricted. Is it trading?
Some people will believe anything, including what some people on this board with personal agendas have to say..................
Lowest short interest in over a year.....
This is so appropriate with respect to PPHM. Can we identify the individuals out there who meet the criteria to work for CRAMER. This said, PPHM will prevail, and these same guys will be on the right side when it happens. Greed is good in their minds.
Or....it can be for BP, to lower their per share cost, which helps us, by them purchasing the remaining shares at a higher price.
Or, it could be a message to BP that we will do it alone if we have to! So dig deeper.....
When will they realize Bavi is the real deal.
Avastin Misses Mark Again in Breast Cancer
Published: Dec 11, 2013
By Charles Bankhead, Staff Writer, MedPage Today
Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco
Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
The addition of bevacizumab (Avastin) to standard adjuvant therapy for HER2-positive breast cancer failed to improve invasive disease-free survival (iDFS) in a randomized clinical trial.
Note that the study suggests that given the negative outcomes in several other studies, the results could spell the end of clinical investigation of anti-angiogenesis inhibitors in breast cancer.
SAN ANTONIO -- The addition of bevacizumab (Avastin) to standard adjuvant therapy for HER2-positive breast cancer failed to improve invasive disease-free survival (iDFS) in a randomized clinical trial.
Patients treated with chemotherapy plus trastuzumab (Herceptin) had 92% iDFS with or without the bevacizumab. Subgroup analysis did not identify any group of patients that benefited from the addition of the angiogenesis inhibitor.
Added to negative outcomes in several other studies, the results could spell the end of clinical investigation of anti-angiogenesis inhibitors in breast cancer, Dennis Slamon, MD, PhD, of the University of California Los Angeles, said here at the San Antonio Breast Cancer Symposium.
"All these anti-angiogenic strategies have really not impacted survival in breast cancer," said Slamon. "There may still be something there if we were able to find the right markers, but, so far, they have all come out negative for any impressive survival advantage.
"The challenge in terms of the safety issues is that if you're not getting a lot of benefit and you're adding safety concerns, you have to wonder whether it's going to be worthwhile pursuing that much further. Unless there is a new drug or new strategy to define the subgroup, I think this is not going anywhere."
Slamon reported findings from the multicenter BETH trial (Bevacizumab and Trastuzumab in HER2-Positive Breast Cancer). The study involved 3,500 patients with early-stage HER2-positive, node-positive breast cancer or high-risk node-negative disease.
Patients received either non-anthracycline or anthracycline-containing chemotherapy and trastuzumab and were randomized to bevacizumab or no additional therapy. The primary endpoint was iDFS, and secondary endpoints included DFS, overall survival, recurrence-free interval, distant recurrence-free interval, and toxicity.
The patients had a median age of 51, almost half were node negative, half had tumors =2 cm, and 59% were hormone-receptor positive.
When the trial ended after a median follow-up of 33 months, it had not met the primary endpoint. Overall survival was 96% to 97% in both treatment groups. Analysis of iDFS according to chemotherapy regimen showed no difference between groups.
The addition of bevacizumab increased the toxicity burden. Patients treated with bevacizumab had a 27% incidence of grade 3/4 adverse events of interest, as compared with 8% in patients who did not receive the angiogenesis inhibitor.
The bevacizumab group had significantly higher rates of hypertension (19% versus 4%, P<0.0001), bleeding (2% versus <1%, P<0.0001), heart failure (2.1% versus <1%, P=0.021), proteinuria (21 cases versus 1, P<0.0001), and gastrointestinal perforation (11 cases versus 1, P<0.031).
Slamon showed results from previous studies to emphasize the progress in breast cancer survival. With surgery alone, long-term DFS was 26%. The introduction of adjuvant therapy increased DFS to 32%, and anthracyline-based therapy added another 4%.
With the introduction of the taxanes, DFS increased to 62%, and then to 67% with dose-dense therapy and 84% with the introduction of targeted therapy. The BETH trial demonstrated iDFS of 92% in both groups.
"We have very little room at the top to think about new strategies for those patients who are not getting the benefit that we had hoped they would with targeted therapy," said Slamon.
The results leave little doubt that angiogenesis inhibitors do not have a role in breast cancer -- HER2-positive disease in this case, said Jennifer Litton, MD, of the University of Texas MD Anderson Cancer Center in Houston.
"This study asked a question that has been ongoing for several years: Whether anti-angiogenesis -- and specifically bevacizumab in this case -- is going to add anything to the current treatment strategies," said Litton, who was not involved in the study. "I feel that Dr. Slamon and his group have definitively answered this in the HER2 question. Bevacizumab adds really significant toxicity and no benefit."
The question. Are they doing their day jobs at night?
maybe going private. Too many shares for the everyday retail. This is so out of the ordinary, even for this stock.........
could this be a reverse merger. something is up?
4:30EST
"I will believe the clear evidence of dose switching when somebody is proven guilty of dose switching. Is that crazy?"
Yes, it is and it is illogical. By your standard a person who is shot twenty five times in the head isn't considered murdered unless someone is convicted of the murder!
The dose switching happened. There is no question about that. It was proven to the satisfaction of the FDA, the body that has jurisdiction over the issue. The only question is why did it happen and by whom!
Which present an excellent lead as to who may have been behind FARGO. MEANS, MOTIVE and OPPORTUNITY!
sounds like someone doesn't like KING. Look at the history of posts!
Tells us about your former employment with Peregrine!
And, it also puts U.S.A. potential partners on notice.....